Its rival Moderna said earlier this month, however, that it has already fully enrolled a 6,000-subject phase 3 study of its quadrivalent vaccine candidate mRNA-1010 in the southern hemisphere ...

Regeneron and Teva have announced positive top-line phase 3 results from their fasinumab, as the companies chase Pfizer and Lilly in the race to market a new class of non-opioid painkillers.